anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Nano-silver-based active ingredient contains 4000ppm Nano-silver as silver nanoparticles and the size distribution of these particles is from 1 to 100 nm. And fight against other harmful single-celled microorganisms in poultry, livestock and aquaculture. Also, with the active ingredient, we can reduce meat fat and increase protein. In a dehydrated environment, the active ingredient can be sprayed on the surface and silver acts as a catalyst. If the process of action of the active ingredient on energy cycle enzymes occurs, ATP production stops and the lack of energy reduces Becomes microorganisms. Silver nanoparticles can be used prophylactically instead of all antibacterial drugs. In the absence of pathogenic microorganisms and their stress on the immune system and other systems of poultry, livestock and aquatic animals, the energy produced can be used to build tissue. Used more. It can also improve weight gain in poultry, livestock and aquatic animals.
Colonoscopy can be challenging to perform and painful due to looping of the colonoscope. Looping occurs when further insertion of the colonoscope results in a loop forming in the shaft of the colonoscope instead of advancement of the tip. Attempts have been made to solve this problem, but to date there is no perfect solution. Since colonoscopy is the gold standard for colon cancer screening providing a device that could prevent looping would be valuable. We have developed an experimental device that has not been approved outside of the context of this study known as the Segmental Stiffening Wire (SSW). This wire will be utilized by passing it through the biopsy channel of the endoscope. The wire has a 15-25 inch area of increased thickness and stiffness. The stiffened section can be advanced into areas of looping in an effort to prevent re-looping. We will conduct a pilot study in two phases. The first phase will include approximately 10 healthy volunteers who will undergo colonoscopy using the SSW. Fluoroscopy will be used to determine if the device prevents re-looping. If in phase 1 the device is successful in over 30% of episodes, the second phase will be undertaken. In the second phase volunteers willing to undergo two colonoscopies on consecutive days will be recruited. Volunteers who experience looping will be randomized as to whether the SSW is available. These volunteers will then undergo an otherwise identical colonoscopy on the following day except the SSW will be available if it was not on the first colonoscopy or it will not be available if it was on the first colonoscopy. Volunteers who undergo two colonoscopies will not need a second bowel preparation but will be maintained on a clear liquid diet between the two procedures. Volunteers in which looping does not occur will have their initial colonoscopy completed as normal and then will leave the study. If unable to obtain sufficient volunteers willing to undergo dual colonoscopy, then volunteers willing to undergo single colonoscopy will be included and their procedures will be done with or without the SSW in random fashion. The endpoints will be cecal intubation time; cecal intubation rate; quantity of sedation/analgesia; number of ancillary maneuvers; pain/sedation as measured by the Visual Analog Pain Scale, the Ramsey Sedation Scale, and clinical observations; vital sign changes; and the endoscopists subjective assessment of procedure difficulty and the usefulness of the SSW.
PURPOSE:To secure a degree of freedom for selection and to improve the way of using by classifying a photographic menu into display groups, and displaying a selected menu according to the display position of a photographic item. CONSTITUTION:Memory 42 stores the display positions of the photographic menus included in plural display groups in which the photographic menus are classified according to arbitrary items. Furthermore, at least the display groups and a picture to select the photographic menu are displayed on a display 16. An arbitrary display group can be selected by observing the display 16. In such a case, the CPU 38 of a controller part 14 is operated so as to display the selected menu according to the display position. A display group selection picture and a selection picture are inputted to a photographic information input part by the selection key 18 of an operating part 12 and the keys 20. Thereby, the menu is displayed according to the display position of the photographic item, therefore, the degree of freedom for selection can be given, and the photographic menu easy to use can be obtained.
[PROBLEMS] To provide a drug or a food for specified health uses aiming at slowing the onset or progress of mobility impairment relating to amyotrophic lateral sclerosis. [MEANS FOR SOLVING PROBLEMS] An agent containing D-allose as the active ingredient and aiming at slowing the onset or progress of mobility impairment relating to amyotrophic lateral sclerosis. A composition in the form of a food, a drink or a drug which contains the agent for slowing the onset or progress as described above. The above-described composition wherein the daily dose of D-allose is from 0.5 to 50 g. A food or a drink containing D-allose as the active ingredient which is indicated as being used for slowing the onset or progress of mobility impairment relating to amyotrophic lateral sclerosis. A method of slowing the onset or progress of mobility impairment relating to amyotrophic lateral sclerosis in a human subject which comprises administering or feeding D-allose in an efficacious amount to the subject. A method of treating a human subject diagnosed as suffering from amyotrophic lateral sclerosis which comprises administering or feeding to the subject D-allose in an efficacious amount for slowing the progress of mobility impairment.
The present invention provides compositions and methods for prevention, amelioration and treatment of gram positive bacteria, particularly <i>Staphylococcal</i> bacteria, with combinations of lysin, particularly Streptococcal lysin, particularly the lysin PlySs2, and one or more antibiotic, including daptomycin, vancomycin, oxacillin, linezolid, or related antibiotic(s). The present invention provides compositions and methods for prevention, amelioration and treatment of gram positive bacteria, particularly <i>Staphylococcal</i> bacteria, with combinations of lysin, particularly Streptococcal lysin, particularly the lysin PlySs2, and one or more antibiotic, including daptomycin, vancomycin, oxacillin, linezolid, or related antibiotic(s). The present disclosure is directed to a coating composition comprising a stabilized color pigment dispersion. This disclosure is further directed to a coating composition comprising a stabilized color pigment dispersion and metallic pigments, such as aluminum flakes. The stabilized color pigment dispersion can comprise at least one phosphated polymer. The coating composition can be applied over a substrate to form a coating layer having stable color and metallic visual effects. The coating composition can be used for vehicle coating, such as OEM or refinish coatings, appliance coatings, or other industrial or consumer coating applications.
Safety and effectiveness of Articaine HCl and Epinephrine in pediatric patients below the age of 4 years have not been established. Safety of doses greater than 7 mg/kg (0.175 mL/kg) in pediatric patients has not been established. The safety and effectiveness of Articaine HCl and Epinephrine for local, infiltrative, or conductive anesthesia in both simple and complex dental procedures have been established in pediatric patients ages 4 to 16 years old. Safety and effectiveness was established in clinical trials with 61 pediatric patients between the ages of 4 and 16 years administered another product containing articaine hydrochloride 4% and epinephrine 1:100,000 injections. Fifty-one of these patients received doses from 0.76 mg/kg to 5.65 mg/kg (0.9 mL to 5.1 mL) of articaine HCl for simple dental procedures and 10 patients received doses between 0.37 mg/kg and 7.48 mg/kg (0.7 mL to 3.9 mL) of articaine HCl for complex dental procedures. Approximately 13% of these pediatric patients required additional injections of anesthetic for complete anesthesia. Safety of doses greater than 7 mg/kg (0.175 mL/kg) of articaine HCl in pediatric patients has not been established. Dosages in pediatric patients should be reduced, commensurate with age, body weight, and physical condition [see Dosage and Administration (2.2)].
Subjects in the GSK2586184 400 mg Arm will receive twice daily dose of GSK2586184 400 mg (2 x 200 mg tablets) orally up to 12 weeks. Study medication should be taken with food, immediately following a meal.
The presence of hypoxic cells in solid tumors is a marker for therapy resistant, aggressive disease. The non-invasive detection of hypoxic cells in tumors by radiolabeled 2-nitroimidazoles is a diagnostic technique under current evaluation. Two peptidic chelating agents, dimethylglycyl-L-seryl-L-cysteinyl-lysyl{N E-[1-(2-nitro-1H-imidazolyl)acetamido]}-glycine (RP435) and dimethylglycyl-tert-butylglycyl-L-cysteinylglycine-[2-(2-nitro-1H-imidazolyl)ethyl]amide (RP535) have been synthesized.  Both chelating agents contain an N3S class chelator for 99m Tc and Re, and a 2-nitroimidazole group which can be enzymatically reduced and trapped in cells under hypoxic conditions. Two isomers of 99m TcO-RP435, which are assumed to be syn and anti conformations, have been observed on HPLC analysis. The interconversion of the two isomers in aqueous solution was investigated. In contrast, RP535 chelates 99m Tc to form a single isomer and no conversion to its counterpart has been observed on HPLC analysis. The tert-butyl group on the chelator may inhibit the formation and interconversion of the syn and anti isomers of 99m TcO-RP535. Both tracers showed a significant degree of hypoxia-specific accumulation in an in vitro assay, with 99m TcO-RP535 showing higher selectivity for hypoxic cells than 99m TcO-RP435.  These results suggest that 99m TcO-RP535 represents a lead compound worthy of further investigation as an agent for imaging hypoxia in tumors.
Therapeutic irradiation to the head and neck for cancer damages salivary glands present in the radiation field. Despite long recognition of radiation-induced salivary hypofunction, and the associated oral morbidities, the specific damage mechanism(s) is not known and the structure and functional integrity of the surviving parenchymal tissue has not been well-documented. Detailed knowledge of the latter is particularly necessary in order to design appropriate corrective therapies. It is the purpose of this study to provide such a detailed structural and functional assessment of human parotid glands following irradiation. The study will examine 20 patients beginning just prior to therapeutic irradiation and continuing at intervals for 3 years for a total of 5 study visits. Study visits (prior to irradiation and at 4 weeks, 12 weeks, 12 months and 36 months post-irradiation) will include the following procedures: i) detailed oral exam and structured interview; ii) salivary gland functional assessment; iii) sialography of each parotid gland; iv) 99mTcO4 scan of the salivary glands; and v) a magnetic resonance imaging (MRI) scan of the parotid glands. Based on previous single observation studies in humans, and more detailed animal studies, we hypothesize that ionizing radiation will lead to reduced parotid gland function and diminished salivary parenchymal tissue (with a preferential loss in acinar versus ductal cells). Further, we hypothesize that the parenchymal loss will increase with time (replaced by fat and connective tissue) and lead to progressive irreversible salivary dysfunction.
Patients receive anticancer therapy as prescribed by their treating clinicians. Patients receive prednisone/prednisolone orally twice on either day 1 or day 8. Patients also receive daunorubicin hydrochloride IV over 30 minutes and vincristine IV once on the same day.
This was an open-label, long-term extension study of afegostat tartrate in participants with type 1 Gaucher disease who successfully completed Study GAU-CL-202 (NCT00446550). Participants could enter the study immediately upon completion of participation in the lead-in study GAU-CL-202, or at any later time point. Participants received 225 milligram (mg) afegostat tartrate, administered orally for 30 months, and remained in 1 of the 2 randomized treatment regimens of Study GAU-CL-202: afegostat tartrate once daily (QD) for 3 consecutive days, then no afegostat tartrate for 4 consecutive days (consecutive 3-days-on/4-days-off) or QD for 7 consecutive days, then no afegostat tartrate for 7 days (consecutive 7-days-on/7-days-off). Amendment 2 removed the 7-days-on/7-days-off regimen and added an alternative 3-days-on/4-days-off regimen: afegostat tartrate QD on Monday, Wednesday, and Friday, then no afegostat tartrate on Tuesday, Thursday, Saturday, and Sunday (MWF 3-days-on/4-days-off). Once Amendment 2 was implemented at a site, participants assigned to the 7-days-on/7-days-off regimen switched to a 3-days-on/4-days-off regimen; those on the original 3-days-on/4-days-off regimen could switch to the MWF 3-days-on/4-days-off regimen. Amendment 4 removed the original 3-days-on/4-days-off regimen and any participants still on that regimen switched to the MWF 3-days-on/4-days-off regimen. Study visits occurred every 3 months for 30 months. Participants were contacted approximately 1, 3, and 6 months after the end of treatment (EOT) or early termination for follow-up assessments.
BACKGROUND: Improving the quality of care is a priority for health systems to obtain better care and reduce costs. One of the tools for measuring quality is benchmarking (BM). We presented a 1-country prospective study of distal pancreatectomies (DPs) and determined BM.
STUDY DESIGN: Prospective, multicenter, observational snapshot study of DP carried out at Spanish hepatopancreatobiliary centers for a year (February 1, 2022, to January 31, 2023). Hepatopancreatobiliary centers were defined as high volume if they performed more than 10 DPs per year. Inclusion criteria include any scheduled DP for any diagnosis and age older than 18 years. The low-risk group was defined following the criteria given by Durin and colleagues and major complications as Clavien-Dindo ≥III.
RESULTS: A total of 313 patients from 42 centers and 46.6% from high-volume centers were included. Median DP by center was 7 (interquartile range 5 to 10), median age was 65 years (interquartile range 55 to 74), and 53.4% were female. The surgical approach was minimally invasive in 69.3%. Major complications were 21.1%. Postoperative pancreatic fistula grade B/C rate was 20.1%, and 90-day mortality was 1.6%. One hundred forty-three patients were in low-risk group (43.8%). Compared with previous BM data, an increasing MIS rate and fewer hospital stay were obtained.
CONCLUSIONS: We present the first determination of DP-BM in a prospective series, obtaining similar results to the previous ones, but our BM values include a shorter hospital stay and a higher percentage of minimally invasive surgery probably related to Enhanced Recovery after Surgery protocols and prospective data collection. BM is a multiparameter valuable tool for reporting outcomes, comparing centers, and identifying the points to improve surgical care.
Placebo gas will be adjusted the same as study gas: to start at 20ppm for the first three days of life. The dose will then be decreased to 10 ppm for three days, 5 ppm for 3 days and then 2 ppm until all high flow respiratory support has been discontinued.
A method for filling a hand held spray device is disclosed. The spray device has a body with a reservoir. The method includes mixing a non-volatile silicone fluid, an antiperspirant active, at least one liquid activation enhancer and a first portion of an organoclay material to form a first composition, wherein the liquid activation enhancer has a Hansen Solubility Parameter for Hydrogen Bonding, .delta. h, between about 2 and about 6 and a light transmittance value greater than 90%. The method further includes mixing a liquid fragrance material and a second portion of an organoclay material to form a second composition. The method further includes filling the reservoir by either mixing the first composition and the second composition to form an antiperspirant composition and adding the antiperspirant composition to the reservoir or by filling the reservoir with the first composition and thereafter filling the reservoir with the second composition after the reservoir is filled with the first composition, to form an antiperspirant composition; attaching a valve to the body; and filling the reservoir with a propellant, wherein the hand held spray device has a propellant concentration after filling from about 30% to about 90% by weight of the total fill of materials within the reservoir.
Perineural invasion (PNI) is defined as the presence of cancer cells along nerves and/or within the epineural, perineural and endoneural spaces of the neuronal sheath.Clinically, PNI is associated with increased tumor recurrence, poor survival after pancreatectomy and pain, an invalidating symptom that may impair quality of life. Pancreatic ductal adenocarcinoma has one of the highest incidences of PNI (70-100%) among all types of cancer, which correlates with a poor prognosis and decreased survival. PNI is a still not uniformly characterized or quantified event, usually it is described only dichotomously ("present" or "absent"), despite some efforts to use a more detailed scoring system. However, these scores are not specifically developed for pancreatic surgical specimen. Vascular invasion (VI), which is assumed to be associated with a more aggressive tumor biology and dissemination, lacks a specific scoring system as well. The primary aim of this study is to validate both retrospectively and prospectively a novel PNI and VI scoring system aimed at a more detailed stratification of perineural invasion, together with an accompanying scoring system for vascular invasion, and correlated them with disease free survival (DFS).
A 52-year-old woman with no significant medical history was referred to our hospital for expedited workup of progressive dysarthria and ataxia over the past year. Prior CT angiography of the head and neck showed no relevant neurologic findings but did reveal miliary lesions in the lung apices, which was later confirmed via dedicated CT chest scan (Fig 1). Review of systems was negative for any respiratory, constitutional, or rheumatologic symptoms, except for new xanthelasma-like lesions over her forehead. She previously had smoked with 20 pack-years and had no TB risk factors. MRI of the face showed a 21-mm mass within the left external temporal fascia. MRI of the head showed diffuse leptomeningeal enhancement, right frontal lobe enhancement, and cerebellar and brainstem T2/fluid-attenuated inversion recovery hyperintensity, which prompted her admission to hospital.
Stroke patients can benefit from motor imagery and mirror therapy, which are easy to perform anytime and anywhere at their convenience. Integrating motor imagery training with task-specific training leads to greater improvements in sit-to-stand performance compared to task-specific training alone. Core exercises, whether performed alone or combined with other therapies, have been shown to influence trunk performance in stroke patients compared to traditional training. Patients who have had strokes can benefit from rehabilitation training that focuses on strengthening their core muscles. This is likely because it thickens the transverse abdominis muscle. Post-stroke patients were able to regain their motor function and sense of independence with the use of motor imagery as an additional resource. It has been shown to be an effective therapeutic strategy for this particular patient population. More than with routine physiotherapy, core stability exercises on both stable and unstable support surfaces improve ambulatory stroke patients' trunk control, core muscular strength, standing weight-bearing symmetry, and balance confidence. Combined action observation and motor imagery therapy may be helpful for neurorehabilitation in chronic stroke survivors when physical practice is not appropriate. Compared to standard physical treatment alone, core stability exercise and conventional physical therapy has demonstrated better outcomes in trunk control and balance.

The combination of motor imagery and core stability exercises remains underexplored in stroke rehabilitation, leaving a significant knowledge gap about their synergistic potential. Investigating their combined effects could offer innovative strategies to improve trunk control, balance, and sleep quality, paving the way for more comprehensive and effective post-stroke treatment programs.
BACKGROUND: There is limited information about the outcomes of polymicrobial bloodstream infections in patients with sepsis. We aimed to investigate outcomes of polymicrobial bloodstream infections compared to monomicrobial bloodstream infections.
METHODS: This study used data from the Korean Sepsis Alliance Registry, a nationwide database of prospective observational sepsis cohort. Adult sepsis patients with bloodstream infections from September 2019 to December 2021 at 20 tertiary or university-affiliated hospitals in South Korea were analyzed.
RESULTS: Among the 3,823 patients with bloodstream infections, 429 of them (11.2%) had polymicrobial bloodstream infections. The crude hospital mortality of patients with sepsis with polymicrobial bloodstream infection and monomicrobial bloodstream infection was 35.7% and 30.1%, respectively (p = 0.021). However, polymicrobial bloodstream infections were not associated with hospital mortality in the proportional hazard analysis (HR 1.15 [0.97-1.36], p = 0.11). The inappropriate use of antibiotics was associated with increased mortality (HR 1.37 [1.19-1.57], p < 0.001), and source control was associated with decreased mortality (HR 0.51 [0.42-0.62], p < 0.001).
CONCLUSIONS: Polymicrobial bloodstream infections per se were not associated with hospital mortality in patients with sepsis as compared to monomicrobial bloodstream infections. The appropriate use of antibiotics and source control were associated with decreased mortality in bloodstream infections regardless of the number of microbial pathogens.
Participants received SAR245408 400 mg once daily or at the established dose as combination regimen in the parental study until disease progression, unacceptable toxicity, withdrawal of consent, or until commercial supplies of SAR245408 were available (up to 1959 days). Commercially available drugs were used as combination medications with SAR245408 (depending on the parental study, the following drugs were used in combination with SAR245408: paclitaxel and carboplatin, letrozole, trastuzumab, paclitaxel and trastuzumab).
Provided are compositions and methods for production of anti-inflammatory cytokines, growth factors, or chemokines. Provided are nucleic acids (e.g., expression vectors) that include an NFκB inflammation response element operably linked to a nucleotide sequence encoding an anti-inflammatory cytokine (e.g., IL-4). In some cases, the nucleic acid is an expression vector selected from: a linear expression vector, a circular expression vector, a plasmid, and a viral expression vector. Also provided are cells (e.g., mesenchymal stem cells - MSCs) comprising a nucleic acid that includes an NFκB inflammation response element operably linked to a nucleotide sequence encoding an anti-inflammatory cytokine. In some cases, the nucleic acid is integrated into the cell's genome. Also provided are methods for treating an individual having an inflammation-associated ailment, which can include administering an MSC to the individual, where the MSC includes an NFκB inflammation response element operably linked to a nucleotide sequence encoding an anti-inflammatory cytokine.